According to a recent LinkedIn post from Function Health, the company is highlighting a member case in which expanded lab testing reportedly identified a critically low ferritin level that routine labs had not detected. The story suggests that this finding led to additional diagnostics and early removal of high-risk precancerous polyps, which the post portrays as significantly improving the member’s health outlook.
The post also underscores that Function Health offers access to more than 160 lab tests on a subscription model priced at $365 per year, positioning its service as a means to gain deeper health insights and potentially intervene earlier in disease progression. For investors, the focus on preventive diagnostics and recurring subscription revenue may indicate a strategy aimed at capturing demand in consumer-directed health testing, which could support longer-term growth if customer acquisition and retention prove sustainable.